Why Heart Failure Treatment Starts with Medications, Not Surgery
When patients hear the words "heart failure," many assume surgery is imminent. That reaction is understandable. But here is something I tell nearly every patient I see in consultation: the foundation of heart failure treatment is medication, not an operation.
As a cardiac surgeon, this may sound counterintuitive coming from me. But after years of operating on hearts and, just as importantly, seeing what happens to patients before and after surgery, I can tell you that the single biggest gap in heart failure care today is not a lack of surgical options. It is the underuse of proven, life-extending medications.
This article is for patients and families who have been diagnosed with heart failure — particularly heart failure with reduced ejection fraction (HFrEF) — and want to understand the drug therapies that form the backbone of modern treatment. If you or a loved one has been told your ejection fraction is below 40%, this information is directly relevant to your care.
Understanding HFrEF GDMT Therapy: The Four Pillars
Guideline-directed medical therapy, or GDMT, is a term you may have encountered in a cardiologist's office or on a discharge summary. It refers to the specific combination of heart failure medications that the American College of Cardiology (ACC) and American Heart Association (AHA) recommend based on the strongest available clinical evidence.
For HFrEF — defined as an ejection fraction of 40% or less — the current guidelines identify four foundational drug classes. These are not interchangeable options. Each one works through a different biological mechanism, and together they provide additive survival benefit. Think of them as four pillars holding up the same roof.
1. ARNI (Sacubitril/Valsartan) or ACE Inhibitor/ARB
Angiotensin receptor-neprilysin inhibitors (ARNIs), sold under the brand name Entresto, represent a major advance in heart failure treatment. The landmark PARADIGM-HF trial demonstrated that sacubitril/valsartan reduced cardiovascular death and heart failure hospitalization by approximately 20% compared to enalapril, which was itself a proven therapy. For patients who cannot tolerate an ARNI, an ACE inhibitor or ARB remains appropriate, but ARNI is the preferred first-line agent.
2. Beta-Blockers
Three specific beta-blockers have proven mortality benefit in HFrEF: carvedilol, sustained-release metoprolol succinate, and bisoprolol. These drugs slow the heart rate, reduce the toxic effects of chronic adrenaline stimulation on the heart muscle, and have been shown in large trials to reduce death by roughly 30-35%. Not all beta-blockers are the same — this is an important distinction. If you are on a beta-blocker not in this list, it is worth asking your doctor why.
3. Mineralocorticoid Receptor Antagonists (MRAs)
Spironolactone and eplerenone block the harmful effects of aldosterone on the heart and kidneys. The RALES trial showed that adding spironolactone to standard therapy reduced mortality by 30% in patients with severe heart failure. These medications require monitoring of potassium and kidney function, but when used appropriately, they are among the most impactful drugs in all of cardiology.
4. SGLT2 Inhibitors
This is the newest pillar, and arguably the most exciting development in heart failure treatment in years. Dapagliflozin (Farxiga) and empagliflozin (Jardiance) — originally developed for diabetes — have shown remarkable benefits in heart failure patients regardless of whether they have diabetes. The DAPA-HF and EMPEROR-Reduced trials each demonstrated significant reductions in heart failure hospitalization and cardiovascular death. According to the 2022 ACC/AHA guidelines, SGLT2 inhibitors are now recommended for all patients with HFrEF.
The Problem: Most Heart Failure Patients Are Not on Optimal Medications
Here is the uncomfortable truth. Despite decades of evidence and clear guideline recommendations, studies consistently show that fewer than 25% of eligible heart failure patients are on all four pillar medications at target doses. A 2023 analysis published in the Journal of the American College of Cardiology found that the gap between guidelines and real-world practice remains staggeringly wide.
Why does this happen? Several reasons:
- Therapeutic inertia. Physicians sometimes do not up-titrate medications to target doses, especially when a patient "feels fine" on a lower dose.
- Side effect concerns. Low blood pressure, elevated potassium, and kidney function changes can occur, and managing these requires close follow-up.
- Fragmented care. A patient may see a primary care doctor, a general cardiologist, and occasionally a heart failure specialist, with no one clinician taking ownership of the medication optimization process.
- Patient awareness. Many patients do not know these medications exist, do not understand why they are important, or stop taking them due to cost or side effects without discussing alternatives.
This matters because optimized GDMT can improve ejection fraction, reduce symptoms, prevent hospitalizations, and extend life — sometimes dramatically. I have seen patients referred for heart transplant evaluation whose hearts improved enough on optimized medications that transplant was no longer necessary. That is not a rare anecdote. It happens more often than most people realize.
When Heart Failure Medications Are Not Enough: The Role of Surgery and Devices
Guideline-directed medical therapy is the starting point, but it is not always the finish line. Some patients will need additional interventions, and as a cardiac surgeon, these are the conversations I have most frequently.
Cardiac Resynchronization Therapy (CRT)
For patients with HFrEF and a wide QRS complex on their electrocardiogram (typically a left bundle branch block pattern with QRS duration greater than 150 milliseconds), a biventricular pacemaker can coordinate the heart's contractions and improve function. This is a well-established therapy supported by multiple randomized trials.
Left Ventricular Assist Devices (LVADs)
When heart failure is advanced and refractory to medications, a mechanical pump can be implanted to support the heart. LVADs are used as a bridge to heart transplant or, increasingly, as long-term ("destination") therapy. This is a major surgical decision with significant implications for quality of life and requires thorough evaluation.
Heart Transplant
Transplantation remains the gold standard for end-stage heart failure, but donor organ availability is limited and the evaluation process is rigorous. Critically, transplant centers generally expect that GDMT has been fully optimized before listing a patient.
Coronary Artery Bypass Grafting (CABG)
In patients whose heart failure is driven by coronary artery disease, restoring blood flow through bypass surgery can sometimes improve heart function. The STICH trial and its long-term follow-up (STICHES) showed a survival benefit for CABG plus medical therapy compared to medical therapy alone in patients with ischemic cardiomyopathy, though patient selection is critical.
Valve Surgery
Significant mitral or aortic valve disease can cause or worsen heart failure. In these cases, surgical or transcatheter valve repair or replacement may be appropriate. But the key question is always: has the medical therapy been optimized first? A patient with severe mitral regurgitation and an ejection fraction of 25% may look very different after three months of proper GDMT.
If you have been told you need heart surgery for a condition related to heart failure, it is worth confirming that your medication regimen has been fully addressed. A cardiac surgery second opinion can help clarify whether your current treatment plan is truly optimized or whether there are medical adjustments that should happen first.
What You Can Do Right Now: Practical Steps for Patients
Managing heart failure effectively requires active participation. Here are concrete steps you can take today:
- Know your ejection fraction. Ask your doctor for the exact number from your most recent echocardiogram. If your EF is 40% or below, all four GDMT pillars should be on the table.
- Review your medication list. Are you on an ARNI (or ACE inhibitor/ARB), an evidence-based beta-blocker, an MRA, and an SGLT2 inhibitor? If not, ask why. There may be a valid medical reason — but there may also be an opportunity for improvement.
- Ask about dose optimization. Being on a medication is not the same as being on the right dose. Each of these drugs has a target dose established in clinical trials. Many patients are maintained on starting doses indefinitely.
- Track your symptoms. Daily weight, exercise tolerance, shortness of breath, and swelling are all important data points. Report changes early rather than waiting for your next scheduled appointment.
- Understand your surgical risk. If surgery has been recommended, use a validated tool like our free cardiac surgery risk calculator to get a baseline understanding of your individual risk profile. This information is valuable when having informed conversations with your surgical team.
- Do not stop medications without guidance. If cost, side effects, or confusion about your regimen is an issue, talk to your prescribing physician. There are often alternatives, assistance programs, or dosing adjustments that can help.
The Bottom Line: Medications Are the Foundation of Heart Failure Treatment
Heart failure is a serious diagnosis, but it is also one of the areas in cardiovascular medicine where treatment has improved the most in recent years. The four-pillar approach to HFrEF GDMT therapy — ARNI, beta-blocker, MRA, and SGLT2 inhibitor — represents a combined mortality reduction that rivals or exceeds many surgical interventions. And yet, the majority of patients are not receiving this full benefit.
Whether you are newly diagnosed, managing chronic heart failure, or facing a decision about surgery or a device, the question to start with is always the same: is my medical therapy truly optimized?
Surgery can be transformative when it is indicated. But it works best when the medical foundation is solid. As a surgeon, I never want to operate on a patient whose heart could improve meaningfully with better medications alone. That is not conservative — it is good medicine.
If you are facing a recommendation for heart surgery related to heart failure and want to know whether your treatment plan — including your medications — has been fully optimized, a WhiteGloveMD second opinion can help. Our reviews are conducted by board-certified cardiac surgeons who evaluate your complete clinical picture, including your GDMT regimen, before weighing in on surgical decisions. Start your review today and get the clarity you deserve.